Navigation Links
Cosmetic Eye Enhancer may Lead to Disfigurement

Polylactic acid (PLA), used as a cosmetic enhancement to decrease volume loss around the eyes, leads to disfigurement when not injected properly . The authors reviewed four cases where patients were injected superficially; all four exhibited nodule development and inflammation.

PLA should not be injected superficially, especially around the eyes, says study author and dermatologist Greg Goodman. This material does not act as a dermal filler, which would be injected superficially to smooth wrinkles, but needs to be placed deeply below the muscles to be a safer and more effective agent.

The technique is still so comparatively new and unproven, however, that Goodman cautions against its use around the eyes unless completed by a doctor who is experienced in its use.

According to Goodman, many cosmetic techniques are implemented too quickly and too carelessly. Practitioners should be wary of new procedures and instruction from representatives who themselves have been recently trained in the procedures, says Goodman.

Goodman also cautions patients against trying the newest products on the market. New procedures are not necessarily the best procedures; sometimes waiting for a procedure to improve and mature over many years is the best policy for those seeking safe, quality results.


'"/>




Page: 1

Related medicine news :

1. Cosmetic plastic surgery for a youthful healthy look
2. How Safe Are Your Cosmetics ?
3. “Yes, I need Cosmetic surgery” – view of majority wome
4. Details of Cosmetic Surgery in a Special Website.
5. More People Come To India For Cosmetic Surgery
6. Transparency in Probable Outcomes of Cosmetic Surgeries Necessary
7. Cosmetic Surgeons Discuss Facelift Surgery
8. Chemical Content in Cosmetic Products may be Harmful for Health
9. Campaign Against Cosmetic Surgeries Performed By Less-Skilled Non-physicians Launched
10. Survey Finds Americans Not Averse To Cosmetic Surgery
11. Do Anti-wrinkle Cosmetics Really Work?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey ... to residential and commercial clients in the northern Alabama and Georgia regions, is ... , Since 1977, Nobis Works has built a network of support and education ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: